Online citations, reference lists, and bibliographies.
← Back to Search

Preparation And Characterization Of Sorafenib-loaded Microprecipitated Bulk Powder For Enhancing Oral Bioavailability.

Ju-Hwan Park, Min-Jun Baek, J. Lee, Ki-taek Kim, Hyun-Jong Cho, Dae-Duk Kim
Published 2020 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The aim of this study was to prepare and evaluate Eudragit-based microprecipitated bulk powder (MBP) formulations to enhance the oral bioavailability of sorafenib. Cationic Eudragit E PO and anionic Eudragit S100 were selected for MBP preparation. Ursodeoxycholic acid (UDCA)-incorporated MBP was also prepared to study the synergistic effect of UDCA in enhancing the bioavailability of sorafenib. Sorafenib-loaded MBPs were successfully prepared by a pH-controlled precipitation method using an aqueous antisolvent. Submicron-sized particles of MBPs were observed by scanning electron microscopy, and the amorphous form of sorafenib in MBPs was confirmed by powder X-ray diffraction. MBPs of cationic and anionic Eudragits showed different in vitro dissolution and pharmacokinetic profiles in rats. Sorafenib in Eudragit E PO-based MBP (E PO-MBP) was rapidly dissolved at low pH conditions (pH 1.2 and 4.0), but was precipitated again at pH 4.0 within 4 h. Dissolution of sorafenib from Eudragit S100-based MBP (S100-MBP) was high at pH 7.4 and did not precipitate for up to 4 h. After oral administration to rats, all MBPs, compared with powder, improved the oral absorption of sorafenib, with S100-MBP showing 1.5-fold higher relative oral bioavailability than E PO-MBP. Moreover, incorporation of UDCA in S100-MBP (S100-UDCA-MBP) further increased the Cmax and oral bioavailability of sorafenib, although the dissolution was not significantly different from that of S100-MBP. Taken together, Eudragit-based MBP formulations could be a promising strategy for enhancing the oral bioavailability of sorafenib.
This paper references
10.1016/j.xphs.2017.07.001
Producing Amorphous Solid Dispersions via Co-Precipitation and Spray Drying: Impact to Physicochemical and Biopharmaceutical Properties.
Amanda K. P. Mann (2018)
10.1124/dmd.110.032052
In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein
M. J. Gnoth (2010)
10.1016/0016-5085(92)90162-R
Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage.
S. Walker (1992)
10.1158/0008-5472.CAN-04-1443
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
10.3109/10717544.2014.896058
Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead
Shambhu Dokania (2015)
10.1007/s40005-013-0058-3
Preparation, characterization and in vitro dissolution of aceclofenac-loaded PVP solid dispersions prepared by spray drying or rotary evaporation method
M. Kim (2013)
10.1016/J.POWTEC.2015.04.044
Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib
D. H. Truong (2015)
10.1634/theoncologist.2009-0088
Sorafenib and sunitinib.
A. Kim (2009)
10.3109/03639049709150502
Enhanced Dissolution of Ursodeoxycholic Acid from the Solid Dispersion
S. Okonogi (1997)
10.1016/S1470-2045(08)70285-7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng (2009)
10.1073/PNAS.82.21.7419
Nasal absorption of insulin: enhancement by hydrophobic bile salts.
G. Gordon (1985)
10.1517/17425247.2013.736962
Eudragit®: a technology evaluation
S. Thakral (2013)
10.3390/molecules20069496
Enhanced Supersaturation and Oral Absorption of Sirolimus Using an Amorphous Solid Dispersion Based on Eudragit® E
Youngseok Cho (2015)
10.4103/0975-7406.171691
Development of pH sensitive polymeric nanoparticles of erythromycin stearate
Sulekha Bhadra (2016)
10.3748/WJG.V12.I22.3487
Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
T. Pusl (2006)
10.1200/JCO.2008.19.5511
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
B. Escudier (2009)
10.1158/1078-0432.CCR-06-1249
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
R. Kane (2006)
10.1002/JPS.10511
Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability.
Ping Gao (2003)
10.1007/s40005-018-0385-5
Canagliflozin loaded SMEDDS: formulation optimization for improved solubility, permeability and pharmacokinetic performance
Dilpreet Singh (2018)
10.1080/21553769.2013.879925
Application of bile acids in drug formulation and delivery
M. Stojančević (2013)
10.2147/IJN.S104119
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer
S. Yang (2016)
10.1007/s40262-013-0108-z
Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
M. Fukudo (2013)
10.1186/s11671-017-2420-2
Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
S. Benizri (2018)
10.1016/S0378-5173(03)00083-8
Factors affecting the apparent solubility of ursodeoxycholic acid in the grinding process.
Han Chung (2003)
10.2147/IJN.S105419
Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique
H. Li (2016)
10.1007/s40005-020-00477-w
Enhanced dissolution and oral bioavailability of poorly water-soluble herb (Kaempferia parviflora) extract using solid dispersions: effect of surfactants and concentrations
Yotsanan Weerapol (2020)
10.1007/s12272-014-0547-6
Enhancement of solubility and dissolution of cilostazol by solid dispersion technique
Jun-Hyung Park (2015)
10.1208/s12249-015-0425-7
Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale
A. Agrawal (2015)
10.1155/2013/848043
Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems
S. Gupta (2013)
10.3109/00365521.2014.898326
Surface area of the digestive tract – revisited
H. Helander (2014)
10.1080/03639045.2016.1241259
Formulation and evaluation of injectable in situ forming microparticles for sustained delivery of lornoxicam
S. Yehia (2017)
10.1517/17425241003596337
Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs
Cai-Xia He (2010)
10.1021/acs.molpharmaceut.5b00837
Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Chengyu Liu (2016)
New therapeutical indications of ursodeoxycholic acid.
I. Copaci (2005)
10.2147/IJN.S24185
Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
Jingling Tang (2011)
10.1016/S0928-0987(99)00093-7
Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine.
S. Michael (2000)
10.22270/JDDT.V3I5.632
SOLUBILITY ENHANCEMENT BY SOLID DISPERSION METHOD: A REVIEW
J. Singh (2013)
10.1016/j.ijpharm.2012.08.031
Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs.
N. Shah (2012)
10.1080/10717544.2016.1245371
Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix
Yang Guo (2017)



Semantic Scholar Logo Some data provided by SemanticScholar